Gan & Lee Pharmaceuticals Co Ltd is a Chinese pharmaceutical company with a medium risk ESG score of 29.6. Specializing in insulin research, development, and production, the company offers a range of biosimilar insulin analogue products for the diabetes market. Their portfolio includes Basalin, Prandilin, and Prandilin 25.